Hospira, a Pfizer company, has announced that they have issued a nationwide voluntary recall of three of their injectable products due to the potential of glass particles in the products.

The recalled products—, 4.2% sodium bicarbonate injection, 1% lidocaine HCI injection and 2% lidocaine HCI injection— have expiration dates of 1 August, 1 June, and 1 July, respectively, in 2024. They were distributed to wholesalers, hospitals, and institutions nationwide in the US and Puerto Rico 13-16 October this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Hospira announced that they have not received reports of any adverse events associated with this issue, but that potential serious adverse events, though highly unlikely, are probable.

Pfizer purchased Hospira back in 2015 in a $17bn acquisition.

This isn’t the first time that Pfizer’s sterile injectables business has faced quality issues.

Back in December last year, Hospira recalled one lot of its vancomycin hydrochloride injection vials packaged at the 1.5-gram dose due to glass particles in the vials. The lot, which comprised of 100 vials, was distributed nationwide in the US.

Earlier in 2022, Hospira issued a voluntary recall for one lot of propofol after a “visible particulate” was found in a vial during an annual inspection. The product was distributed nationwide in the US to wholesalers, hospitals, and the US Department of Defence in June 2020.

In the announcement by the US Food and Drug Administration (FDA), Pfizer said it places an emphasis on patient safety and product quality at every step in the manufacturing and supply chain process.